Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: A retrospective analysis

Jair Bar*, Dawn Ng, Patricia Moretto, Glenwood D. Goss, Alexander Sun, Robert Macrae, Scott A. Laurie, Natasha Leighl, Garth Nicholas

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Even if non-small-cell lung cancer (NSCLC) is diagnosed early and resected, recurrence is common. Uncertainty exists about the optimal treatment of locoregional recurrence. In fit patients with locoregional recurrence, chemoradiotherapy is sometimes offered, but no data exist about the feasibility and efficacy of this approach. We retrospectively collected data from patients treated this way to assess their outcomes and to identify prognostic factors. Patients and Methods: Databases of The Ottawa Hospital Cancer Centre (TOHCC) (N = 5791) and the Princess Margaret Hospital (PMH) (N = 2225) were screened to identify patients with recurrent NSCLC after curative resection who were offered curative-intent chemoradiotherapy. Selected patients' charts were reviewed. Results: Thirty patients fit our search criteria. The median disease-free interval was 15 months (2-33 months) and stage at recurrence was mainly T0 (n = 25 [83%]), N2 (n = 25 [83%]), and M0 (n = 29 [97%]). The median radiation dose given at recurrence was 63.5 Gy (26-66 Gy). Chemotherapy included a platinum agent in all cases, mostly a platinum-vinorelbine doublet (n = 14 [47%]), at a median of 3 cycles, (1-6 cycles) 2 of which were concurrent (0-3 cycles). Toxicities were as expected from thoracic chemoradiotherapy, with 7 cases of grade 4 toxicities and no treatment-related deaths. Median follow-up was 22 months (1.5-88 months). Median survival after recurrence was 26.9 months. No prognostic factors were identified. Conclusion: Chemoradiotherapy for locoregional recurrent NSCLC is practiced sporadically. This treatment is feasible for highly selected patients, and in our cohort, it allowed for a significantly higher than expected survival. No prognostic factors were identified. Chemoradiotherapy for locoregional NSCLC should be examined in a prospective trial.

Original languageEnglish
Pages (from-to)200-204
Number of pages5
JournalClinical Lung Cancer
Issue number2
StatePublished - Mar 2013
Externally publishedYes


  • Chemoradiotherapy
  • Mediastinal recurrence
  • Non-small-cell lung cancer
  • Retrospective analysis


Dive into the research topics of 'Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: A retrospective analysis'. Together they form a unique fingerprint.

Cite this